Latest Strategic Reset News

Synlait Milk Limited reveals a challenging first half of 2026 with significant losses expected, as it pivots its operations around Canterbury following the upcoming sale of its North Island assets.

Ryman Healthcare has unveiled a refreshed strategy focused on growing recurring earnings and optimising its portfolio, targeting a $150 million sustainable cash flow improvement and $500 million cash release by FY29. The company plans to resume dividends from FY28, underpinned by a resilient balance sheet and disciplined capital management.

ClearVue Technologies advances its building-integrated solar tech with new product breakthroughs and global commercial projects, while strengthening its financial footing and board expertise.

AuMake Limited reports positive operating cashflow and a strategic pivot into China’s high-growth OTC medicine market, supported by a $1.5 million capital raise and significant governance reforms.

Aland Equity Group Limited has completed significant capital raisings and board restructuring while navigating a challenging quarter for its flagship Growth Fund. The company is positioning itself for expansion into property funds management.

Adheris Health reported a sharp decline in Q2 FY26 revenue but is pushing ahead with leadership changes, cost cuts, and a new digital platform to reshape its future.

QMines Limited has made significant strides in its Queensland projects with high-grade drilling results at Mount Mackenzie and Develin Creek, backed by a $9 million capital raise to support exploration and development.

Mach7 Technologies reports a positive operating cash flow in Q2 FY26, securing its first customer for the new Flamingo Architecture product and advancing key strategic initiatives.

NT Minerals faces ASX trading suspension but pushes forward with exploration plans at Twin Peaks and Finniss River projects, while considering capital restructuring.

Vitura Health has announced the departure of CEO Geoff Cockerill, appointing Chief Revenue Officer Ryan Tattle as interim leader while accelerating the search for a new CEO. Incoming CFO Andrew Cook will join ahead of schedule, signalling a renewed focus on operational and financial discipline.

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Altech Batteries has reported a significant technical milestone with its Silumina Anodes™ technology achieving 88.5% capacity retention after 500 cycles, alongside a $6 million capital raise and a strategic board renewal focused on commercialisation.